On Friday, Cullinan Therapeutics Inc (NASDAQ: CGEM) opened lower -3.15% from the last session, before settling in for the closing price of $11.74. Price fluctuations for CGEM have ranged from $5.68 to $13.78 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -45.66% over the past five years. Company’s average yearly earnings per share was noted -30.30% at the time writing. With a float of $39.43 million, this company’s outstanding shares have now reached $59.08 million.
Cullinan Therapeutics Inc (CGEM) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cullinan Therapeutics Inc is 33.26%, while institutional ownership is 77.35%. The most recent insider transaction that took place on Nov 24 ’25, was worth 49,200. In this transaction Chief Scientific Officer of this company sold 4,000 shares at a rate of $12.30, taking the stock ownership to the 138,004 shares. Before that another transaction happened on Nov 24 ’25, when Company’s Officer proposed sale 4,000 for $9.47, making the entire transaction worth $37,880.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.73 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.74) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.02% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Check out the current performance indicators for Cullinan Therapeutics Inc (CGEM). In the past quarter, the stock posted a quick ratio of 10.45. For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.68, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -3.13 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 2.37 million, a positive change from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 67.56%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 74.38%, which indicates a significant increase from 67.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.03 in the past 14 days, which was higher than the 0.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.80, while its 200-day Moving Average is $7.93. Nevertheless, the first resistance level for the watch stands at $11.84 in the near term. At $12.30, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.60. If the price goes on to break the first support level at $11.08, it is likely to go to the next support level at $10.78. Assuming the price breaks the second support level, the third support level stands at $10.32.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are currently 59,076K shares outstanding in the company with a market cap of 671.70 million. Presently, the company’s annual sales total 0 K according to its annual income of -167,380 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -50,610 K.
